Table 3.
Summary of reduction in Eczema Area and Severity Index and Investigator Global Assessment score from baseline
| Visit category | AK120 treatment groups | Placebo (N = 9) |
||||
|---|---|---|---|---|---|---|
| 75 mg QW (N = 8) |
150 mg QW (N = 8) |
300 mg QW (N = 8) |
300 mg Q2W (N = 8) |
Total (N = 32) |
||
| Day 8 | 8 | 8 | 8 | 7 | 31 | 9 |
| EASI 50, n (%) | 2 (25.0) | 1 (12.5) | 2 (25.0) | 1 (14.3) | 6 (19.4) | 0 (0.0) |
| EASI 75, n (%) | 1 (12.5) | 1 (12.5) | 0 (0.0) | 0 (0.0) | 2 (6.5) | 0 (0.0) |
| IGA score 0 or 1, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| IGA reduction from baseline of ≥ 2 points, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Day 15 | 8 | 8 | 7 | 8 | 31 | 9 |
| EASI 50, n (%) | 1 (12.5) | 5 (62.5) | 3 (42.9) | 2 (25.0) | 11 (35.5) | 2 (22.2) |
| EASI 75, n (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| IGA score 0 or 1, n (%) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) | 1 (3.2) | 0 (0.0) |
| IGA reduction from baseline of ≥ 2 points, n (%) | 0 (0.0) | 1 (12.5) | 0 (0.0) | 1 (12.5) | 2 (6.5) | 1 (11.1) |
| Day 22 | 8 | 8 | 7 | 8 | 31 | 8 |
| EASI 50, n (%) | 2 (25.0) | 6 (75.0) | 4 (57.1) | 4 (50.0) | 16 (51.6) | 1 (12.5) |
| EASI 75, n (%) | 1 (12.5) | 2 (25.0) | 1 (14.3) | 1 (12.5) | 5 (16.1) | 0 (0.0) |
| IGA score 0 or 1, n (%) | 1 (12.5) | 0 (0.0) | 1 (14.3) | 0 (0.0) | 2 (6.5) | 0 (0.0) |
| IGA reduction from baseline of ≥ 2 points, n (%) | 1 (12.5) | 0 (0.0) | 2 (28.6) | 1 (12.5) | 4 (12.9) | 0 (0.0) |
| Day 29 | 8 | 8 | 7 | 8 | 31 | 8 |
| EASI 50, n (%) | 3 (37.5) | 7 (87.5) | 4 (57.1) | 6 (75.0) | 20 (64.5) | 1 (12.5) |
| EASI 75, n (%) | 1 (12.5) | 4 (50.0) | 4 (57.1) | 2 (25.0) | 11 (35.5) | 0 (0.0) |
| IGA score 0 or 1, n (%) | 1 (12.5) | 4 (50.0) | 1 (14.3) | 2 (25.0) | 8 (25.8) | 0 (0.0) |
| IGA reduction from baseline of ≥ 2 points, n (%) | 2 (25.0) | 4 (50.0) | 2 (28.6) | 2 (25.0) | 10 (32.3) | 0 (0.0) |
| Day 43 | 7 | 8 | 7 | 8 | 30 | 8 |
| EASI 50, n (%) | 2 (28.6) | 6 (75.0) | 4 (57.1) | 4 (50.0) | 16 (53.3) | 0 (0.0) |
| EASI 75, n (%) | 1 (14.3) | 5 (62.5) | 2 (28.6) | 3 (37.5) | 11 (36.7) | 0 (0.0) |
| IGA score 0 or 1, n (%) | 1 (14.3) | 3 (37.5) | 2 (28.6) | 1 (12.5) | 7 (23.3) | 0 (0.0) |
| IGA reduction from baseline of ≥ 2 points, n (%) | 2 (28.6) | 3 (37.5) | 3 (42.9) | 1 (12.5) | 9 (30.0) | 0 (0.0) |
| Day 57 | 8 | 8 | 7 | 7 | 30 | 8 |
| EASI 50, n (%) | 4 (50.0) | 7 (87.5) | 5 (71.4) | 4 (57.1) | 20 (66.7) | 0 (0.0) |
| EASI 75, n (%) | 1 (12.5) | 3 (37.5) | 4 (57.1) | 2 (28.6) | 10 (33.3) | 0 (0.0) |
| IGA score 0 or 1, n (%) | 1 (12.5) | 1 (12.5) | 1 (14.3) | 0 (0.0) | 3 (10.0) | 0 (0.0) |
| IGA reduction from baseline of ≥ 2 points, n (%) | 2 (25.0) | 2 (25.0) | 2 (28.6) | 0 (0.0) | 6 (20.0) | 0 (0.0) |
| Day 85 | 8 | 8 | 7 | 8 | 31 | 7 |
| EASI 50, n (%) | 3 (37.5) | 5 (62.5) | 3 (42.9) | 4 (50.0) | 15 (48.4) | 1 (14.3) |
| EASI 75, n (%) | 1 (12.5) | 2 (25.0) | 2 (28.6) | 1 (12.5) | 6 (19.4) | 0 (0.0) |
| IGA score 0 or 1, n (%) | 1 (12.5) | 1 (12.5) | 1 (14.3) | 0 (0.0) | 3 (9.7) | 0 (0.0) |
| IGA reduction from baseline of ≥ 2 points, n (%) | 2 (25.0) | 2 (25.0) | 1 (14.3) | 0 (0.0) | 5 (16.1) | 0 (0.0) |